Interferon Beta-1B

Introduction Overview

Generic Name

interferon beta-1b

Brand Name

Extavia

Dosage Form

Injectable solution (single-dose vial or prefilled syringe for subcutaneous injection)

Drug Class

Interferons

Pharmacokinetics

Absorption:
Interferon beta-1b (Extavia) is administered via subcutaneous injection, leading to systemic absorption. Following a single subcutaneous dose, peak serum concentrations are typically reached within 3 to 15 hours. The bioavailability is approximately 30% to 50% due to degradation by proteolytic enzymes at the injection site and during absorption. The absorption phase is influenced by local blood flow and tissue factors at the injection site. Clinical data indicates that the absorption kinetics remain consistent with repeat dosing, supporting a steady state with chronic administration.

Distribution:
Once absorbed, interferon beta-1b distributes primarily in the extracellular fluid space. It exhibits low plasma protein binding, allowing high availability to peripheral tissues and immune cells. Distribution volume is approximately equivalent to extracellular water volume, reflecting limited tissue sequestration. Interferon beta-1b does not significantly cross the blood-brain barrier; however, it exerts immunomodulatory effects peripherally that impact central nervous system disease activity. Pharmacokinetic studies have not demonstrated accumulation in specific organs.

Metabolism:
Interferon beta-1b, being a recombinant protein, is metabolized predominantly by proteolytic enzymes in systemic circulation and targeted tissues, breaking down into smaller peptides and amino acids. Unlike small molecules, it is not metabolized via cytochrome P450 enzymes, minimizing drug-drug metabolic interactions. Metabolic processing occurs both intracellularly and extracellularly, with immune cells internalizing the interferon via receptor-mediated processes. The metabolism rate is influenced by factors such as immune activity and patient-specific variables including presence of neutralizing antibodies.

Elimination:
The elimination half-life of interferon beta-1b is approximately 4 to 8 hours following subcutaneous administration. The compound is eliminated mainly via proteolytic catabolism rather than renal or hepatic excretion of intact drug. No significant excretion of unchanged interferon beta-1b occurs in urine or feces. The effective clearance is maintained by enzymatic degradation in the blood and tissues. Due to its biological nature, dose adjustments in renal or hepatic impairment are generally not required, but clinical monitoring is prudent.

Dosage Forms

Available Dosage Forms:
Extavia is supplied as a sterile, lyophilized powder and a sterile solution diluent in separate vials, which must be reconstituted prior to use. Alternatively, it is also available as a prefilled syringe in solution form for subcutaneous injection. Each administration uses a single-dose vial or prefilled syringe intended for one-time use only. The formulation includes mannitol and albumin as stabilizers.

Dosages for Adults and Adolescents:
The recommended dosing regimen for adults with relapsing forms of multiple sclerosis starts with an initial titration phase to reduce flu-like side effects. The titration schedule is as follows:
- Weeks 1 and 2: 0.0625 mg (25% of maintenance dose) subcutaneously every other day
- Weeks 3 and 4: 0.125 mg (50% of maintenance dose) subcutaneously every other day
- Weeks 5 and 6: 0.1875 mg (75% of maintenance dose) subcutaneously every other day
- Week 7 and onward: 0.25 mg subcutaneously every other day (maintenance dose)
Adolescents have not been adequately studied; safety and efficacy in pediatric populations remain undetermined.

Specific Patient Populations:
Extavia is not recommended during pregnancy due to potential teratogenicity and risk of miscarriage. Breastfeeding safety has not been established; consult healthcare providers for risk-benefit assessments. No dosage adjustments have been firmly established for hepatic or renal impairment, but patients with pre-existing liver conditions require close monitoring of liver function tests. Elderly patients may require careful observation, although no dosage changes are universally recommended.

The reconstituted solution should be refrigerated and used within 3 hours; do not freeze. Unmixed vials can be stored at controlled room temperature, avoiding moisture and heat. Single-use vials or prefilled syringes must be properly disposed of after use in accordance with biohazard regulations.

Mechanism Of Action

Extavia contains interferon beta-1b, a cytokine belonging to the interferon family which plays a pivotal role in the modulation of the immune system in multiple sclerosis (MS). Its primary molecular mechanism involves binding to specific type I interferon receptors expressed on the surface of various immune cells, including lymphocytes and antigen-presenting cells. This binding activates the JAK-STAT signaling pathway leading to transcriptional activation of numerous interferon-stimulated genes.

At the cellular level, interferon beta-1b enhances the breakdown of pro-inflammatory T-helper 1 cells and upregulates anti-inflammatory cytokines such as interleukin-10. It reduces antigen presentation and inhibits the migration of autoreactive lymphocytes across the blood-brain barrier into the central nervous system, thereby mitigating inflammation and demyelination characteristic of MS.

Biochemically, interferon beta-1b downregulates the expression of matrix metalloproteinases and adhesion molecules, which contribute to blood-brain barrier disruption and immune cell infiltration. Its antiviral and antiproliferative effects further modulate disease pathology. Clinical implications include a reduction in the frequency and severity of MS relapses, a delay in disability progression, and decreased formation of new lesions on MRI.

Comparatively, interferon beta-1b differs from similar agents such as interferon beta-1a in its molecular structure and glycosylation patterns. Extensive clinical studies have demonstrated comparable efficacy and safety profiles, though specific pharmacodynamic properties may vary. Research into neutralizing antibodies and receptor interactions continues to inform personalized treatment strategies with Extavia.

Pharmacological Actions

Immunomodulation via activation of type I interferon receptors.
Inhibition of pro-inflammatory cytokines and upregulation of anti-inflammatory cytokines.
Reduction of lymphocyte proliferation and trafficking into the central nervous system.
Enhancement of blood-brain barrier integrity through downregulation of adhesion molecules.
Antiviral activity contributing to reduced viral triggers of autoimmunity.
Induction of apoptosis in autoreactive immune cells.
Modulation of antigen presentation by dendritic cells and macrophages.
Suppression of matrix metalloproteinase activity to prevent CNS tissue damage.
Reduction in formation of new inflammatory lesions in multiple sclerosis.
Improvement in clinical outcomes such as relapse rate and disability progression.

Therapeutic Or Clinical Uses

Treatment of relapsing forms of multiple sclerosis (MS) including relapsing-remitting MS.
Reduction in the frequency of clinical exacerbations in MS patients.
Patients following a first clinical demyelinating event with MRI evidence predictive of MS.
Management of MS aimed at delaying disease progression and disability accumulation.
Used as an immunomodulatory therapy to modify the natural course of MS.
May be employed in combination with symptomatic therapies for comprehensive MS management.
Off-label use not established; primarily indicated for FDA-approved MS indications.
Therapy initiation to be carefully considered in women of childbearing potential due to pregnancy risks.

Side Or Adverse Effects

Injection site reactions including pain, redness, swelling, and rash.
Flu-like symptoms such as fever, chills, sweating, and muscle aches.
Headache and general weakness.
Abnormal liver function tests indicating hepatotoxicity.
Low white blood cell counts (leukopenia) and anemia.
Sleep disturbances including insomnia.
Depression, mood changes, and in rare cases suicidal ideation.
Allergic reactions, including urticaria and anaphylaxis in rare cases.
Seizures in predisposed individuals.
Symptoms of lupus-like syndrome such as joint pain and photosensitive rash.
Nausea, vomiting, and gastrointestinal discomfort.
Bruising or bleeding tendencies due to blood cell count alterations.
Elevated risk of thyroid dysfunction requiring periodic monitoring.
Injection site necrosis reported rarely.
Potential for neutralizing antibody development reducing efficacy.

Precautions

Screen patients for history of depression or suicidal tendencies before initiation.
Regular monitoring of liver function tests is essential due to hepatotoxic risk.
Avoid use in patients with known hypersensitivity to interferon beta, albumin, or mannitol.
Monitor thyroid function periodically during therapy.
Use caution in patients with seizure disorders; consider risk-benefit.
Patients with bleeding or blood clotting disorders require careful evaluation.
Advise against use during pregnancy; effective contraception recommended in women of childbearing potential.
Educate patients on proper injection technique to minimize site reactions.
Do not inject into infected, red, or tender skin areas.
Use with caution in patients with pre-existing liver or heart disease.
Avoid concomitant use with other immunosuppressive therapies unless medically justified.
Monitor blood counts periodically to detect cytopenias early.
Inform patients about possible flu-like side effects and strategies for management.
Advise on avoidance of alcohol consumption due to additive liver risk.
Assess for latex allergy as some injection devices may contain latex components.

Warnings

Extavia may cause fetal harm and is contraindicated during pregnancy.
Associated with risk of severe depression and suicidal ideation; monitor mental health closely.
Potential for hepatotoxicity requiring frequent liver function monitoring.
Risk of neutralizing antibodies that may reduce therapeutic efficacy over time.
Injection site necrosis and severe allergic reactions have been reported.
Patients with seizure disorders may experience worsening of seizures.
May exacerbate autoimmune conditions such as lupus erythematosus.
Cardiovascular adverse effects including chest tightness and heart failure symptoms.
Use caution in patients with hematologic abnormalities; risk of cytopenias.
Do not share needles or syringes to prevent infection transmission.
Delayed hypersensitivity reactions possible; discontinue if severe reactions occur.
Monitor for signs of infection due to immunomodulatory effects.
Frequent clinical and laboratory follow-up is recommended to identify adverse effects early.
Avoid abrupt discontinuation to prevent disease rebound.
Patients should report any new or worsening neurological symptoms promptly.

Contraindication

Known hypersensitivity to interferon beta-1b or any component of the formulation including albumin and mannitol.
Pregnancy due to potential teratogenicity and risk of miscarriage.
Severe hepatic impairment or active liver disease.
Severe psychiatric disorders with suicidal ideations or severe depression not controlled.
History of severe allergic reactions to interferons.
Use in children and adolescents below 18 years, safety and efficacy not established.
Patients with known hypersensitivity to latex if devices contain latex components.
Concomitant use with other immunomodulatory biologics without medical supervision.

Drug Interactions

Potential additive immunosuppressive effects when used with other immunomodulators or chemotherapy agents.
No significant cytochrome P450-mediated drug interactions due to protein metabolism.
Caution advised with drugs affecting liver function; may increase hepatotoxicity risk.
Concurrent use with other interferons may increase adverse effects.
Non-steroidal anti-inflammatory drugs (NSAIDs) may exacerbate flu-like symptoms.
Rare interactions reported with corticosteroids; clinical monitoring recommended.
Possible increased risk of seizures when used with pro-convulsant drugs.
Interactions with anticoagulants may alter bleeding risk due to blood cell count changes.
No clear interaction data with vitamins or herbal products; consult healthcare provider.
Concomitant administration with live vaccines not recommended due to immunomodulatory effects.
Potential interaction with antiepileptic drugs warranting dose monitoring.
Combined use with alcohol can potentiate liver injury.
Interaction with psychotropic medications possible; monitor for additive CNS effects.
No known significant interactions with oral contraceptives, but pregnancy category contraindicates use in pregnancy.
Monitor for unexpected reactions with any new medications during interferon therapy.

Preparations Of The Drug

Extavia is provided as a lyophilized powder in a single-dose vial requiring reconstitution with supplied diluent prior to subcutaneous injection.
Additionally available as a prefilled syringe containing sterile solution for subcutaneous use.
Each single-use vial or syringe contains 0.25 mg of interferon beta-1b per dose.
Formulations include stabilizers such as human albumin and mannitol to ensure protein stability.
Packaging includes sterile needles for injection, though some kits require separate needle purchase.
Instructions for use are provided with each preparation outlining reconstitution and injection procedures.
Storage conditions require unmixed vials to be kept at controlled room temperature away from moisture and heat.
Reconstituted solution must be refrigerated and used within 3 hours; do not freeze the product.
Single-dose administration system designed to prevent multi-use contamination and ensure dosing accuracy.
Proper disposal containers and guidelines are recommended for used syringes and needles.
Preparation kits may include alcohol swabs and sharps disposal containers depending on region.
Biosimilar products such as Betaseron (also interferon beta-1b) are available with similar formulations for clinical use.
Packaging designed to facilitate self-administration by patients following proper training.
Manufactured under sterile conditions consistent with biologic therapeutic standards.
Lot numbers and expiration dates are clearly indicated to ensure product integrity.